The top after-market NASDAQ losers Monday were: Neurocrine Biosciences, Nektar Therapeutics, Apollo Group, ValueVision Media, Gen-Probe, Hi-Tech Pharmacal, Harmonic, Techne Corp, Expedia and Myriad Genetics.
Neurocrine Biosciences, Inc. (NBIX) stock slumped 8.57 percent to $8.22 in aftermarket session. The company announced that results from a phase II trial of its treatment for tardive dyskinesia patients did not meet the primary endpoint.
Nektar Therapeutics (NKTR) stock plunged 4.07 percent to $7.55 in aftermarket session. The company stock gained more than 3 percent in regular session.
Apollo Group, Inc. (APOL) stock plunged 3.98 percent to $41.48 in aftermarket session. The company swung to second quarter net income of 63.9 million or $0.51 per share compared to net loss of $64.0 million or $0.45 per share in the same period a year-earlier. Revenue declined to $969.55 million from $1.05 billion in the same period last year.
ValueVision Media, Inc. (VVTV) stock plunged 3.48 percent to $2.22 in post market session.
Gen-Probe Inc. (GPRO) stock declined 3.26 percent to $65.56 in aftermarket trading. The stock has a 52-week low of $53.92, a 52-week high of $89.96 and $3.07 billion in market capitalization.
Hi-Tech Pharmacal Co., Inc. (HITK) stock declined 2.84 percent to $37.00 in aftermarket session. The company stock climbed more than 4 percent in regular trading.
Harmonic Inc. (HLIT) stock fell 2.83 percent to $5.50 in post market trading.
Techne Corp. (TECH) stock declined 2.78 percent to $68.23 in post market session. The stock has a 52-week low of $62.04, a 52-week high of $86.43 and $2.59 billion in market capitalization.
Expedia, Inc. (EXPE) stock declined 2.43 percent to $34.58 in aftermarket trading. The company announced that it has entered into a definitive agreement to acquire VIA Travel.
Myriad Genetics, Inc. (MYGN) stock declined 2.4 percent to $22.78 in aftermarket session. The company announced that he Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al to the Federal Circuit Court of Appeals.